Further studies are in progress to assess the mechanism of the clinical effect on dysmenorrhoea as well as the optimal dosage and therapy

intervals. This study supports the hypothesis that pertubation with 10 mg of lignocaine is safe and indicates that it might be possible to try a higher dose to further improve the clinical effect on pain. 5 Conclusions Lignocaine pertubated through the fallopian tubes reaches the peritoneal cavity and diffuses through the peritoneum into the blood circulation. The serum levels of lignocaine following pertubation of 10 mg lignocaine hydrochloride are detectable but low. AZD1152 Pertubation with lignocaine is safe and produces no lignocaine-related adverse events. Acknowledgments The authors thank the research unit, Danderyd Hospital, Stockholm, Sweden, for excellent practical support with the clinical trial patients. We also thank OncoTargeting AB for the professional handling of the serum samples. The study was financed with an unconditional research grant from the Stockholm County Council, Sweden. There was no connection between the Stockholm County Council and the implementation of the project. None of the authors have competing interests. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are

ICG-001 clinical trial credited. References 1. Cambridge GW, Parsons JF, Friend JV, Jones PA. Some effects of lignocaine on

cultured mouse peritoneal macrophages. Agents Actions. 1985;16(6):548–51.PubMedCrossRef 2. Hollman MW, Durieux ME. Local anesthetics and the inflammatory response. Anesthesiology. 2000;93(3):858–75.CrossRef 3. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D. Is endometriosis associated with systemic subclinical inflammation? Gynecol Obstet Invest. 2006;62(3):139–47.PubMedCrossRef 4. Berkley KJ, Rapkin AJ, Papka RE. The pains of endometriosis. Science. 2005;308(5728):1587–9.PubMedCrossRef Teicoplanin 5. Christodoulakos G, Augoulea A, Lambrinoudaki I, Sioulas V, Creatsas G. Pathogenesis of endometriosis: the role of defective ‘immunosurveillance’. Eur J Contracept Reprod Health Care. 2007;12(3):194–202.PubMedCrossRef 6. Medina MG, Lebovic DI. Endometriosis-associated nerve fibers and pain. Acta Obstet Gynecol Scand. 2009;88(9):968–75.PubMedCrossRef 7. Edelstam GAB, Sjösten ACE, Salamon CW. Pertubation with lignocaine-a possible new treatment for women with endometriosis and impaired fertility. Ups J Med Sci. 2001;106:51–8.PubMedCrossRef 8. Edelstam G, Sjösten A, Jablonowska B, Kjellberg S, Spira J. Pertubation with lidocaine—a non-hormonal, long-term treatment of dysmenorrhea due to endometriosis. Sex Reprod Healthc. 2012;3(2):93–4. 9. Edelstam G, Sjösten A, Bjuresten K, Ek I, Wånggren K, Spira J. A new rapid and effective method for treatment of unexplained infertility. Hum Reprod. 2008;23(4):852–6. 10. Yagiela JH.